NEWARK, DE — New preclinical research from CorriXR Therapeutics suggests a novel gene-editing strategy could reopen the door ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
Study in Molecular Therapy Oncology shows gene editing restores drug sensitivity by targeting NRF2, with potential across multiple tumor types In a major step forward for cancer care, researchers at ...
A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...
Image Caption: Mechanisms of resistance to chemoradiotherapy in osteosarcoma. In chemoradiotherapy resistant OS cells, altered expression of the drug transporter proteins, RFC and ABC family, reduces ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
Backed by more than 30 peer-reviewed human clinical studies supporting endogenous antioxidant activity, cellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results